CGON

Cg Oncology Inc.

CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -23.33% and +80.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

The consensus price target hints at a 29.8% upside potential for CG Oncology, Inc. (CGON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here is how Brainsway Ltd. Sponsored ADR (BWAY) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year.

CG Oncology, Inc. (CGON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CG Oncology (NASDAQ:CGON) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cg-oncology-inc-common-stock-stock...

Pictet Asset Management Holding SA lifted its position in shares of CG Oncology, Inc. (NASDAQ:CGON - Free Report) by 2.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,349,527 shares of the company's stock after...

Wall Street Zen cut CG Oncology from a "hold" rating to a "sell" rating in a research note on Saturday...

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director James Mulay sold 15,600 shares of the business's stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director directly owned...